Advaxis, a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, announced today that Daniel J. O’Connor, Senior VP, Chief Legal, and Business Development Officer at Advaxis, will be presenting at the BIO International Convention (BIO 2013) in Chicago, IL, later this week.
On April 22 at 3:00pm, Mr. O’Connor will provide a review of the progress of ADXS-HPV, Advaxis’ lead drug candidate in Phase 2 clinical development for recurrent/refractory cervical cancer. Updated data regarding this exciting compound will be disclosed at the 2013 American Society of Clinical Oncology Annual Meeting in June.
Recognized as the largest global event for biotechnology and pharmaceutical industries, the BIO International Convention attracts many of the biggest names across all major continents. This year’s convention was organized to provide valuable networking and partnering opportunities, as well as generate insights and inspirations on current trends that are essential in the development of innovative and better technologies for the future.
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment